biostudies-literatureLENS Collaborative GroupMedical Research CouncilNational Institute for Health Research (NIHR)e15310https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617915biostudies-literatureUnknown41(9)<h4>Background</h4>Findings from cardiovascular outcome trials suggest that treatment with fenofibrate may reduce the progression of diabetic retinopathy. However, no dedicated large-scale randomised trials have yet investigated this hypothesis.<h4>Methods</h4>LENS is a streamlined randomised double-masked placebo-controlled trial, based in Scotland, assessing whether treatment with fenofibrate (145 mg tablet daily or, in the context of impaired renal function, on alternate days) in people with early retinopathy reduces progression to referable diabetic retinopathy (defined in NHS Scotland's Diabetic Eye Screening grading scheme as referable background or proliferative retinopathy, or referable maculopathy in either eye) or treatment with retinal laser, intravitreal injections or vitrectomDiabetic medicine : a journal of the British Diabetic AssociationDesign, recruitment and baseline characteristics of the LENS trial.PMC761791514/49/84HDR-23004Young AWood SWallendszus KBaxter AVirdi MTaggart DClark CMcAllister CLittle JWhitelaw LDuffy KPatel PTaylor KSammons EMartin LStewart LWincott LDarling JHughes EDuncan MTodd ABurgess FColhoun HCutting CBlackwell SJenkins DCadzow AAitSadi RMeek JMurphy EWillett MBeck DBeesley MBeveridge LPettifor CAdigwe GJWatkins AMcChlery GLyons TYoung IBailey LChamberlain AAchiri PLister LVarikkara MHoward CMostafi YZettegren PThomson AFinlayson LLocke JFinlayson JMalcolm ESattar NSawyer KZayed MHoward SStyles CTurner LBird KCarty DNeill PWhite AZachariah SPostovalova EPhilip SBagley GWilson AFathers SGray KWilson EBlaikie AGoonasekera MLogue JBradley CElliott FGilmour AGill AArmitage JFowler SSpata ESpeirs SHallard GHalls HThompson JMcDonald MBrown GSedstrem KBodansky JLENS Collaborative GroupPeddie HKnott CCui GField ARoure IMurray LLeese GNeely DCairns ABurke ACretney RFreeman NDoig JWade RMcGregor AGreig SMciIntyre MCharlwood KBerry CPark SCoventry TMistry MCurrie GRaff RMacliver LJones LStaplin NHurley SBegg AMackenzie IGoodenough BBrogan SOlson JWhitehouse ABarton IMilne LStevens WRyan LJoseph SQuigley JTimadjer AHerlihy OFawcett SMurphy KLiew ASweeney AWilliamson PRaj MBoytha SSharp KEmberson JHarding SDickie SPirie SConnelly PSyed SLindsay JBell ELindsay RDaniels CKurien RLay MVandenberg KPreiss DBell MMadill KWild SBrown MO'Keeffe LBrown KScotland GPickworth SToye JHewick SMurawska AfalseDesign, recruitment and baseline characteristics of the LENS trial.<h4>Background</h4>Findings from cardiovascular outcome trials suggest that treatment with fenofibrate may reduce the progression of diabetic retinopathy. However, no dedicated large-scale randomised trials have yet investigated this hypothesis.<h4>Methods</h4>LENS is a streamlined randomised double-masked placebo-controlled trial, based in Scotland, assessing whether treatment with fenofibrate (145 mg tablet daily or, in the context of impaired renal function, on alternate days) in people with early retinopathy reduces progression to referable diabetic retinopathy (defined in NHS Scotland's Diabetic Eye Screening grading scheme as referable background or proliferative retinopathy, or referable maculopathy in either eye) or treatment with retinal laser, intravitreal injections or vitrectom2024-01-01T00:00:00Z2024 Sep2026-06-08T06:47:54.266Z2025-08-30T03:05:54.086ZS-EPMC76179153838558710.1111/dme.15310